- Reuters•3 days ago
Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market. Investors had been making space for the well-telegraphed deal ever since Teva announced its US$40.5bn acquisition of Allergan Generics earlier in the year, while declining rates across the developed world and a lack of recent supply in the US and European markets added impetus to the transaction. In Europe, Teva issued bonds that priced up to 35bp inside its secondary curve - and those outstanding bonds, in turn, tightened by an incredible 40bp during the execution process.
- Bloomberg•4 days ago
Teva Pharmaceutical Industries Ltd. sold Swiss-franc denominated bonds and said it had raised enough money in a sweep of markets worldwide to close a $40.5 billion acquisition.
Teva Pharmaceutical Industries LimitedNYSE
After hours: 54.790.06 (0.11%) as of 4:23 PM EDT
|Bid||54.61 x 100|
|Ask||54.89 x 100|
|52wk Range||48.01 - 72.31|
|Day's Range||54.34 - 54.96|
|Avg Vol (3m)||6,303,419|
As of 4:02 PM EDT. Market closed.